Spero Therapeutics
Katie (Keane) McClure, CPA has a diverse work experience in the financial field. Katie most recently worked at Spero Therapeutics as the Associate Director of FP&A. Prior to that, they held the position of Senior Manager of Financial Planning & Analysis at Beam Therapeutics. Katie also had previous roles at Spero Therapeutics as the Finance Manager of FP&A and Senior Financial Analyst of FP&A. Katie gained experience at Codiak BioSciences as a Senior Financial Analyst and Senior Accountant. Earlier in their career, Katie worked at PwC as an Experienced Associate in the Insurance & Banking Practice. Katie has also been involved in educational roles, serving as a Financial Accounting Teaching Assistant at the University of Connecticut. Katie started their career as an Assurance Intern at PwC and completed finance internships at bluebird bio.
Katie (Keane) McClure, CPA obtained their Bachelor of Science degree in Accounting from the University of Connecticut School of Business, graduating in 2015. Katie has not obtained any additional certifications at this time.
Spero Therapeutics
2 followers
Spero Therapeutics (Nasdaq: SPRO) is a multi-asset pre-commercial stage biopharmaceutical company in Cambridge, Mass. We are highly committed to advancing novel treatment approaches for bacterial infections with a world-class team of biotechnological and biopharmaceutical experts. The company has a pipeline of novel and highly differentiated antibacterial and rare disease product candidates focused on patients' unmet needs with multi-drug resistant (MDR) bacterial infections.